Loading data for HURA — first visit, this takes a few seconds.
TuHURA Biosciences, Inc.
2.03 +0.00 (0.00%)
2.06 -1.80%
- Capitalización de mercado
- $133.8M
- Volumen
- 108K
- Próxima fecha de resultados
- Nov 13, 2026
TuHURA Biosciences, Inc. (HURA): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $0 | n/a | n/a |
| EPS | -$0.14 | +$0.01 | +33.33% |
Métricas
- Precio de compra
- 1.48
- Ingresos (TTM)
- n/a
- Beneficio neto (TTM)
- -30.6M
- n/a
- -0.54
- n/a
- -3.47
- P/B (TTM)
- 7.34
- P/S (TTM)
- n/a
- Fecha de resultados
- Nov 13, 2026
- Precio de venta
- 2.58
- Volumen
- 108,074
- Volumen medio (20D)
- 388,773
- Abierto
- 2.03
- Anterior Cerrar
- 2.03
- Rango del día
- 2.01 - 2.10
- Rango de 52 semanas
- 0.41 - 3.43
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de TuHURA Biosciences, Inc.
Ver perfil →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
Industria Biotechnology
Sector Healthcare
IPO Fecha Feb 22, 2013
Empleados 22
Bolsa de Valores NasdaqCM
Símbolo bursátil HURA
Sitio web https://www.tuhurabio.com